Summary
Stryker Corporation reported a solid first quarter for 2017, demonstrating robust top-line growth driven by strong performance across its key segments. Net sales increased by 18.4% to $2,955 million, with 18.8% growth in constant currency, signaling effective execution and market penetration, particularly in the MedSurg segment which saw a significant 36.2% increase. Despite increased operating expenses, including higher R&D and amortization costs stemming from recent acquisitions, the company managed to grow net earnings by 10.4% to $444 million, translating to a diluted EPS of $1.17. The company also continued its commitment to shareholder returns through dividend payments and significant share repurchases. Financially, Stryker maintained a strong liquidity position with $3,213 million in cash and cash equivalents and $66 million in marketable securities. The company's balance sheet shows total assets of $20,517 million and total liabilities of $10,813 million. While the company faces ongoing litigation, notably the Rejuvenate and ABG II hip stem recalls, for which it has set aside substantial reserves, its core operations are performing well. Management highlighted strong organic sales growth, excluding acquisitions and currency impacts, indicating underlying business strength. The company's strategic focus on innovation and expansion through acquisitions appears to be yielding positive results, positioning it for continued growth in the medical technology sector.
Financial Highlights
51 data points| Revenue | $2.96B |
| Cost of Revenue | $991.00M |
| Gross Profit | $1.96B |
| R&D Expenses | $192.00M |
| SG&A Expenses | $1.10B |
| Operating Expenses | $1.41B |
| Operating Income | $556.00M |
| Net Income | $444.00M |
| EPS (Basic) | $1.19 |
| EPS (Diluted) | $1.17 |
| Shares Outstanding (Basic) | 373.40M |
| Shares Outstanding (Diluted) | 379.30M |
Key Highlights
- 1Net sales surged by 18.4% to $2,955 million, with 18.8% growth in constant currency, indicating strong demand and successful integration of acquisitions.
- 2The MedSurg segment was a standout performer, with net sales increasing by 36.2%, driven by strong performance in endoscopy, instruments, and medical products.
- 3Net earnings grew by 10.4% to $444 million, and diluted EPS increased by 9.3% to $1.17, demonstrating effective profitability management.
- 4The company maintained a healthy liquidity position with $3,213 million in cash and cash equivalents at the end of the quarter.
- 5Stryker repurchased approximately $230 million of its common stock, underscoring its commitment to returning value to shareholders.
- 6Research, Development, and Engineering expenses increased by 20.8%, reflecting continued investment in innovation and new technologies.
- 7The company provided an updated range for the estimated probable loss related to the Rejuvenate and ABG II hip stem recalls, indicating ongoing management of this significant liability.